Idefirix Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to organ shortage for kidney transplantation, high prevalence of donor specific antibodies, limitations of traditional desensitization methods, early clinical success of imlifidase, growth in transplant centers.

The growth in the forecast period can be attributed to rising demand for kidney transplants, expansion of transplant waiting lists, increasing adoption of precision immunology, supportive regulatory pathways, growth in specialized transplant clinics. Major trends in the forecast period include rising use of desensitization therapies in transplantation, growing focus on highly sensitized patients, expansion of enzyme based immunomodulation, increasing kidney transplant volumes, improved access to advanced transplant care.

The increasing prevalence and incidence of kidney diseases are expected to drive the growth of the idefirix market. Kidney diseases are conditions that impair the kidneys' ability to filter waste and maintain fluid balance, leading to dysfunction or structural damage. The rising prevalence and incidence of these diseases can be attributed to factors such as an aging population, increasing rates of diabetes and hypertension, lifestyle choices, and genetic predispositions. Idefirix, an innovative immunoglobulin G (IgG)-degrading enzyme therapy, assists kidney disease patients by enabling highly sensitized individuals to undergo life-saving kidney transplants. It effectively reduces donor-specific antibodies that could otherwise lead to transplant rejection. For instance, in June 2023, a report published by Kidney Research, a UK-based organization, projected that the incidence of acute kidney injury would rise from an estimated 615,000 cases in 2022 to 637,000 by 2033. Therefore, the growing prevalence and incidence of kidney diseases is contributing to the growth of the idefirix market.

A key trend in the idefirix market is the focus on developing innovative solutions, such as desensitization treatments, for highly sensitized kidney transplant patients. Desensitization treatment is a medical procedure that reduces or removes harmful antibodies, allowing transplant patients to receive organs from incompatible donors. For example, in July 2023, Hansa Biopharma, a Sweden-based biopharmaceutical company, announced that the Australian Therapeutic Goods Administration (TGA), a regulatory authority in Australia, had approved Idefirix (imlifidase) as a desensitization treatment for highly sensitized kidney transplant patients. This approval enables patients to receive kidney transplants from both living and deceased donors by reducing or removing anti-donor antibodies that could otherwise prevent transplantation. This approval, based on positive results from Hansa Biopharma's phase 2 studies, marks a significant advancement in expanding kidney transplant options for highly sensitized patients in Australia.

In January 2024, Hansa Biopharma AB entered into a partnership with NewBridge Pharmaceuticals, a UAE-based pharmaceutical company, to expand patient access to its desensitization therapy for kidney transplantation. The partnership aims to leverage NewBridge's regional commercial capabilities and regulatory expertise to enhance the availability of Idefirix.

Major companies operating in the idefirix market are Hansa Biopharma AB.

Europe was the largest region in the idefirix market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the idefirix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the idefirix market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the idefirix market by increasing costs for importing enzyme production materials, biologic processing equipment, and sterile formulation components. These effects are most evident in hospital based transplant centers across regions dependent on imported biologics such as europe and asia pacific. Elevated costs can influence therapy pricing and access. However, tariffs are also encouraging regional biomanufacturing investments and localized supply chains for transplant biologics.

The idefirix market research report is one of a series of new reports that provides idefirix market statistics, including idefirix industry global market size, regional shares, competitors with a idefirix market share, detailed idefirix market segments, market trends and opportunities, and any further data you may need to thrive in the idefirix industry. This idefirix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Idefirix (imlifidase) is an enzyme-based medication designed to reduce donor-specific antibodies in highly sensitized kidney transplant patients, facilitating successful organ transplantation. It works by desensitizing patients awaiting kidney transplants through the cleavage of IgG antibodies, thereby increasing compatibility with available donors.

The primary patient demographics for Idefirix include both pediatric and adult patients. Pediatric patients are children or adolescents who require medical care that is specifically adapted to their developmental and physiological needs. Idefirix is used in applications such as kidney transplantation and desensitization protocols. The end users of Idefirix include hospitals, specialized clinics, and home healthcare providers. It is distributed through channels such as direct sales and pharmacies.

The idefirix market consists of sales of lyophilized powders and injectable solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.